Kura Oncology, Inc. KURA
We take great care to ensure that the data presented and summarized in this overview for Kura Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KURA
View all-
Suvretta Capital Management, LLC New York, NY7.65MShares$82.7 Million5.88% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$75.2 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$62.7 Million4.92% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$58.4 Million1.97% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.33MShares$46.8 Million3.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.2MShares$45.4 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.54MShares$38.2 Million1.04% of portfolio
-
Bvf Inc San Francisco, CA3.37MShares$36.4 Million2.09% of portfolio
-
Holocene Advisors, LP New York, NY2.69MShares$29 Million0.23% of portfolio
-
State Street Corp Boston, MA2.67MShares$28.8 Million0.0% of portfolio
Latest Institutional Activity in KURA
Top Purchases
Top Sells
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Insider Transactions at KURA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
526
-2.22%
|
$8,416
$16.03 P/Share
|
|
May 20
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,615
-3.65%
|
$57,530
$22.15 P/Share
|
|
Jan 30
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,825
-11.06%
|
$101,325
$21.55 P/Share
|
|
Jan 29
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,158
-7.3%
|
$121,686
$17.8 P/Share
|
|
Jan 29
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,496
-6.48%
|
$25,432
$17.8 P/Share
|
|
Jan 29
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,053
-2.89%
|
$34,901
$17.8 P/Share
|
|
Jan 29
2024
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
2,318
-1.56%
|
$39,406
$17.8 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
91,052
-95.95%
|
$1,821,040
$20.23 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
91,052
+48.95%
|
$455,260
$5.48 P/Share
|
|
Jan 02
2024
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+39.43%
|
-
|
|
Jan 02
2024
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 02
2024
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+29.65%
|
-
|
|
Dec 07
2023
|
Troy Edward Wilson President and CEO |
SELL
Bona fide gift
|
Indirect |
1,000
-0.36%
|
-
|
|
Dec 07
2023
|
Troy Edward Wilson President and CEO |
SELL
Bona fide gift
|
Direct |
2,000
-78.16%
|
-
|
|
Jun 16
2023
|
Thomas Malley |
BUY
Open market or private purchase
|
Indirect |
50,000
+26.38%
|
$550,000
$11.5 P/Share
|
|
Jun 02
2023
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Direct |
27,966
-91.62%
|
-
|
|
Jun 02
2023
|
Troy Edward Wilson President and CEO |
BUY
Other acquisition or disposition
|
Indirect |
308,394
+25.37%
|
-
|
|
Jun 02
2023
|
Troy Edward Wilson President and CEO |
SELL
Other acquisition or disposition
|
Indirect |
862,212
-41.78%
|
-
|
|
Feb 16
2023
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,125
+50.0%
|
-
|
|
Feb 16
2023
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+27.89%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 82.5K shares |
|---|---|
| Exercise of conversion of derivative security | 91.1K shares |
| Open market or private sale | 112K shares |
|---|---|
| Bona fide gift | 3K shares |